UTHSCSA Faculty Profiles v1.0

Mahalingam, Devalingam

School of Medicine
(210) 450-5970

I currently serve as a clinical faculty member and the leader of the gastrointestinal and interim co-leader of the genitourinary malignancies program at the Cancer Therapy and Research Center (CTRC), The University of Texas Health Science Center at San Antonio (UTHSCSA). I graduated with a medical degree (MB BCh BAO) from the National University of Ireland, Galway (NUIG) in June 2000. Following medical graduation I went on to complete 3 years of internal medicine training and a further 4 years of medical oncology fellowship in Ireland. During this time I also successfully completed my PhD research, entitled ?Identification of selective regulators of TRAIL induced apoptosis?, and was conferred a Ph.D. from National University of Ireland in June 2009. The focus of my PhD was laboratory based, and pertains to pre-clinical drug development targeting the apoptotic/autophagy pathway, in particular the TRAIL signaling pathway and developing DR5-selective TRAIL recombinant pro-apoptotic proteins in ovarian, colon and cervical tumor models. This funded research was conducted in collaboration with researchers at the University Medical Centrum Groningen, Netherlands. My Ph.D. research work has resulted in three original papers as first author as well as patents pertaining to novel TRAIL apoptotic therapeutic agents. These endeavors at international centers have also helped me translate my pre-clinical experience to early clinical trials and importantly establish continued collaboration with these institutions.

With this background and my interest to continue the pursuit of identifying novel cancer therapeutics, I continued my training at the world renowned Institute of Drug Development at UTHSCSA as an advance fellow in Oncology in August 2008. This was the stepping stone to my academic career as a clinical faculty member in the Division of Hematology/Oncology in Sept 2009, with 75% of my time dedicated to clinical research with a primary focus in upper gastrointestinal (GI) malignancies, prostate cancer and early therapeutic clinical studies. In the 6 years to date at UTHSCSA, I have successfully completed a National Cancer Institute (NCI) R21 funded investigator initiated Phase 1 clinical study, as Principle Investigator (PI), analyzing the effects of autophagy inhibition as a mechanism to overcome resistance to cancer treatment. This study has since led to two expansion studies in patients with renal and colon cancer,and more recently a randomized study assessing autophagy inhibition in colon cancer funded through CPRIT (R01 type funding). I also have opened 5 other investigator-initiated clinical studies at the CTRC as lead PI with clinical data on these studies maturing in 2015-2017. I recently served as lead US PI for an international colon cancer study funded through Pledpharma, as well as clinical study chair for two further multi-center phase 2 studies for patients with advance HCC and colorectal cancer, where I was directly involved in its protocol development and study progression. Finally, I serve as PI for 10-12 aditional clinical studies, all of which are listed in this CV.

Apart from clinical research, I continue to collaborate with our basic and translational researchers at UTHSCSA in effort to further elucidate the mechanism of action of novel therapeutic agents. Some of these collaborations have resulted in local and federal funding, as well as high impact publications. My commitment to research also includes teaching fellows, residents and medical students. Over the last 5 years I have mentored five fellows on various research activities pertaining to clinical and translational research. Finally I have published over 40 manuscripts, written book chapters, presented results of my clinical research in formal scientific seminars including the annual meetings for the American Association of Cancer Research, American Society for Clinical Oncology, Irish Society for Medical Oncology, and the EORTC-NCI-AACR international meetings.

My ultimate goal is to pursue a career as a physician and translational researcher in pursuit of identifying novel therapeutic targets in particular for patients with GI and GU malignancies. My hope is that these novel cancer agents that I help develop will someday benefit patients I treat locally, and the many patients suffering from cancer nationally and the world internationally.

9/2014 - Present Associate Professor / Clinical and Associate Professor of Medicine UTHSCSA CTRC, Medicine, San Antonio, TX
9/2013 - Present Medical Oncology Faculty Baptist St Luke's Hospital, Medicine, San Antonio, TX
1/2011 - Present Leader Gastrointestinal Malignancies and Director UT Health Science Center at Cancer Therapy and Research Center, Medicine, San Antonio, TX
9/2009 - Present Medical Oncology Faculty University Hospital, Medicine, San Antonio, TX